All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis.

BACKGROUND

Limited literature exists on the mortality burden of generalized pustular psoriasis (GPP) in the US.

OBJECTIVE

To compare all-cause mortality among patients with GPP with matched populations of patients with plaque psoriasis (PsO) and the general population in the US.

METHODS

An observational study was conducted using US claims data collected between January 1, 2016 and December 31, 2019. All-cause mortality was evaluated at 365 days post-index and at maximum follow-up in the following cohorts: , , , , and . Propensity score matching was used to balance covariates between cohorts. The index date was the first medical claim for GPP (ICD-10 code L40.1) or PsO (L40.0), and a randomly selected date per year for individuals in the cohort.

RESULTS

1246 patients were included in , 1384 in , 2630 in and 127,540 in . 19,641,441 individuals were included in . The maximum follow-up ranged from 36.14 to 41.28 months (3.01-3.44 years). At 365-day follow-up, mortality risk was significantly higher in the vs the (hazard ratio [HR] 4.93, 95% confidence interval [CI] 2.24-10.88) and (HR 2.31, 95% CI 1.32-4.04) cohorts. At maximum follow-up, the mortality risk for the cohort was four times higher than the (HR 3.98, 95% CI 2.92-5.43) and 1.5 times higher than the (HR 1.49, 95% CI 1.20-1.85) cohorts.

CONCLUSION

Patients with GPP exhibited an elevated mortality risk in comparison to the matched and cohorts.